Certolizumab pegol vs placebo: Any severe adverse event during maintenance treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Certolizumab pegol vs placebo Serious adverse events during remission maintenance treatment(1 RCT, 428 participants) Outcome: occurrence of infection, blood and lymphatic system disorder, immune system disorder, neoplasm, demyelinating disorders, drug‐induced systemic lupus er... · people with Crohn's disease who responded to CZP remission‐induction treatment Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty). Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease (2022) · Cochrane Headline outcomes only | RR 0.84 [0.4, 1.78] | Not reported | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.